Mexico - Women's share of population ages 15+ living with HIV (%)

Women's share of population ages 15+ living with HIV (%) in Mexico was 17.70 as of 2020. Its highest value over the past 30 years was 19.20 in 2017, while its lowest value was 16.70 in 1991.

Definition: Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population ages 15+ who are living with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 16.90
1991 16.70
1992 17.40
1993 17.50
1994 17.60
1995 17.80
1996 17.80
1997 17.90
1998 18.00
1999 18.00
2000 18.10
2001 18.20
2002 18.20
2003 18.30
2004 18.30
2005 18.30
2006 18.30
2007 18.30
2008 18.30
2009 18.30
2010 18.30
2011 18.30
2012 18.30
2013 18.50
2014 18.70
2015 18.80
2016 18.90
2017 19.20
2018 18.90
2019 18.80
2020 17.70

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors